The U.S. Food and Drug Administration has suggested that bisphosphonate and risk for atypical subtrochanteric femur fractures may be linked.
According to the My Canadian Pharmacy recent reports, there is an increased interest in the question about whether patients with osteoporosis have an increased risk in this type of fracture when using these medications. That is why, FDA Drug Safety Communication has revealed no definite connection between bisphosphonate and an increased risk of atypical subtrochanteric femur fractures.